Shares of Repros Therapeutics Inc (NASDAQ:RPRX) are trading down considerable in early trading this morning, coming off of a 45.1% gain late last week.
The run up in share price on Friday was because of expected FDA results later today on a drug called Enclomiphene that the company has been working on.
With their FDA PDUFA review and subsequent results expected today, shares may have gotten a bit ahead of themselves, as investors seem to be selling off shares, perhaps taking some profits off the table. A favorable review by the FDA could spark a rapid rise in share price, however, negative results could send shares well below the $1.50 level. We will be paying close attention to this stock throughout the day and hope to do a followup report once news hits. The stock is down 8.13% or $0.21 after the negative news, hitting $2.33 per share. About 124,246 shares traded hands. RPRX has declined 69.10% since April 27, 2015 and is downtrending. It has underperformed by 68.21% the S&P500.
Out of 3 analysts covering Repros Therapeutics (NASDAQ:RPRX), 0 rate it “Buy”, 1 “Sell”, while 2 “Hold”. This means 0 are positive. Repros Therapeutics was the topic in 4 analyst reports since August 20, 2015 according to StockzIntelligence Inc. Ladenburg Thalmann downgraded the stock on October 30 to “Neutral” rating. Brean Capital downgraded the shares of RPRX in a report on October 30 to “Hold” rating.
The institutional sentiment decreased to 0.74 in Q2 2015. Its down 0.46, from 1.2 in 2015Q1. The ratio turned negative, as 23 funds sold all Repros Therapeutics Inc shares owned while 19 reduced positions. 16 funds bought stakes while 15 increased positions. They now own 14.48 million shares or 5.86% less from 15.38 million shares in 2015Q1.
Sarissa Capital Management Lp holds 1.86% of its portfolio in Repros Therapeutics Inc for 1.13 million shares. Destrier Capital Management Llc owns 329,030 shares or 0.57% of their US portfolio. Moreover, Rtw Investments Llc has 0.48% invested in the company for 229,364 shares. The New York-based General American Investors Co Inc has invested 0.35% in the stock. Baker Bros. Advisors Lp, a New York-based fund reported 1.96 million shares.
Repros Therapeutics, Inc. is a biopharmaceutical firm focused on the development of new drugs to treat hormonal and reproductive system disorders. The company has a market cap of $56.75 million. The Company’s product candidates include Androxal and Proellex. It currently has negative earnings. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.